Ovid Therapeutics Reports First-in-Human Safety Data for Novel KCC2 Direct Activator OV350
核心洞察
Ovid Therapeutics successfully completed a Phase 1 study of OV350, the first-ever direct activator of KCC2 (搜索) (potassium-chloride cotransporter 2) tested in humans, demonstrating good safety profile with no treatment-related serious adverse events.
The study achieved pharmacologically active concentrations and showed exploratory qEEG findings consistent with expected KCC2 (搜索) modulation effects in the brain, supporting the therapeutic potential of this novel mechanism.
Results support advancement of Ovid's oral KCC2 (搜索) direct activator portfolio, with OV4071 (搜索) planned for Phase 1/1b trials in Q2 2026 targeting psychosis in Parkinson's disease (搜索) and Lewy body dementia (搜索).
Ovid Therapeutics has achieved a significant milestone in neurological drug development, reporting successful Phase 1 results for OV350, the first-ever direct activator of potassium-chloride cotransporter 2 (KCC2 (搜索)) tested in humans. The study demonstrated a good safety profile while providing proof-of-concept data for targeting this novel therapeutic mechanism in brain disorders characterized by neuronal hyperexcitability.
Phase 1 Study Demonstrates Safety and Target Engagement
The randomized, placebo-controlled, single-ascending dose study evaluated OV350 in 16 healthy participants across two dose cohorts (50 mg and 100 mg), administered via intravenous infusion over ten minutes. The study met its primary objectives of evaluating safety, tolerability, and pharmacokinetics.
"OV350 is a valuable tool program that supported human safety for drugging KCC2 (搜索), an entirely new therapeutic target in the brain, which could be a master switch to curb neural hyperexcitability," said Meg Alexander, President and Chief Operating Officer of Ovid Therapeutics.
Key safety findings included no treatment-related serious adverse events and no treatment-related laboratory findings. The most frequent treatment-emergent adverse event was headache, with some participants experiencing nausea and vomiting that coincided with food intake and were attributed to secondary off-target pharmacology unique to OV350.
Pharmacological Activity Supports Mechanism Validation
The study achieved exposure levels at expected pharmacologically active concentrations, reinforcing the potential for clinical development of KCC2 (搜索) direct activators. Exploratory quantitative electroencephalography (qEEG) findings showed central activity and spectral power consistent with expected physiological effects of KCC2 modulation, occurring contemporaneously with expected brain exposure of OV350.
Pharmacokinetic results aligned with predictions and will inform dosing strategies for future KCC2 (搜索) development programs. However, Ovid does not intend to advance the intravenous OV350 program further, having prioritized oral formulations for chronic use.
Advancing Oral KCC2 Portfolio with Enhanced Potency
The results support advancement of Ovid's portfolio of oral KCC2 (搜索) direct activators, with development candidate OV4071 (搜索) showing twenty-fold greater potency than OV350 in pharmacodynamic disease models. The company expects to submit regulatory applications for a Phase 1/1b clinical trial of OV4071 in Q1 2026, with study initiation planned for Q2 2026.
The initial indication for OV4071 (搜索) targets psychosis associated with Parkinson's disease (搜索) and Lewy body dementia (搜索), conditions with high unmet need where traditional atypical antipsychotics are typically contraindicated. Ovid is also planning to characterize OV4071's pharmacodynamic effects in additional neuropsychiatric conditions, including schizophrenia (搜索) and psychoses or agitation associated with neurodegenerative conditions like Alzheimer's disease (搜索).
Novel Mechanism Addresses Neuronal Hyperexcitability
KCC2 (搜索) is a neuron-specific chloride transporter that maintains inhibitory balance in the brain by enabling gamma-aminobutyric acid (GABA) to exert its inhibitory effect. Direct activation of KCC2 represents a differentiated, mechanism-based approach to treating neurological and neuropsychiatric conditions where neuronal hyperexcitability is central to disease manifestation.
Ovid's KCC2 (搜索) programs are designed to build a first-in-class franchise targeting restoration of excitatory/inhibitory balance in the brain, potentially offering therapeutic benefit across multiple neurological and neuropsychiatric disorders.
Leadership Strengthened with CNS Development Expertise
Concurrent with these clinical advances, Ovid announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through global regulatory approval, including her leadership role in the development and global approvals of Zolgensma, the first gene therapy for spinal muscular atrophy (搜索) at Novartis Gene Therapies (搜索).
"Petra brings a compelling combination of creative drug development, regulatory experience and the deep care of a physician who has treated people suffering from complex neurological conditions," said Alexander. Dr. Kaufmann joins from Vigil Neuroscience, where she served as Chief Medical Officer before the company's acquisition by Sanofi.
Broader Pipeline Development
Beyond KCC2 (搜索) activators, Ovid is developing OV329, a next-generation GABA-aminotransferase (搜索) inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications. The company continues advancing next-generation KCC2 activators from its proprietary library of compounds designed for both oral and injectable formulations.